Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tenecteplasa en dosis baja para el tratamiento del accidente cerebrovascular isquémico agudo en pacientes de edad avanzada (DATE-AGING)

1 de noviembre de 2026 actualizado por: Zhenhua Zhou, Southwest Hospital, China

Eficacia y Seguridad de la Tenecteplasa en Dosis Bajas para el Tratamiento del Ictus Isquémico Agudo en Pacientes Ancianos: Un Estudio Prospectivo, Multicéntrico, Aleatorizado y Controlado

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

806

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Anshan, Porcelana
        • Anshan Changda Hospital
      • Anyang, Porcelana
        • Anyang People's Hospital
      • Anyang, Porcelana
        • Huaxian People's Hospital of Henan
      • Baoshan, Porcelana
        • Baoshan People's Hospital
      • Bijie, Porcelana
        • People's Hospital of Zhijin County
      • Chongqing, Porcelana
        • Chongqing University Three Gorges Hospital
      • Chongqing, Porcelana
        • Chongqing University Jiangjin Hospital
      • Chongqing, Porcelana
        • Bishan Hospital
      • Chongqing, Porcelana
        • Chongqing Emergency Medical Center
      • Chongqing, Porcelana
        • Chongqing University Fuling Hospital
      • Chongqing, Porcelana
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing, Porcelana
        • People's Hospital Of Xiushan County
      • Chongqing, Porcelana
        • The People's Hospital of Dazu Chongqing
      • Chongqing, Porcelana
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing, Porcelana
        • The People's Hospital of Rongchang Chongqing
      • Chongqing, Porcelana
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing, Porcelana
        • The Seventh People's Hospital of Chongqing
      • Chongqing, Porcelana
        • Tongliang Hospital
      • Chongqing, Porcelana
        • Yunyang County People's Hospital
      • Dali, Porcelana
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou, Porcelana
        • Dazhou Central Hospital
      • Deyang, Porcelana
        • The People's Hospital of Zhongjiang
      • Guang’an, Porcelana
        • Guang an People's Hospital
      • Guiyang, Porcelana
        • Guizhou Provincial People's Hospital
      • Guiyang, Porcelana
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin, Porcelana
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi, Porcelana
        • Xunxian People's Hospital
      • Heyuan, Porcelana
        • Heyuan People's Hospital
      • Huanggang, Porcelana
        • Qichun People's Hosiptal
      • Jianyang, Porcelana
        • The People's Hospital Of Jianyang City
      • Laixi, Porcelana
        • Laixi People's Hospital
      • Leshan, Porcelana
        • People's Hospital of Leshan
      • Leshan, Porcelana
        • Leshan Geriatric Specialized Hospital
      • Luoyang, Porcelana
        • Luoyang Mengjin People's Hospital
      • Nanchong, Porcelana
        • Nanbu People's Hospital
      • Pujiang, Porcelana
        • Puyang People's Hospital
      • Pujiang, Porcelana
        • The People's Hospital of Nan Le Xian
      • Shangqiu, Porcelana
        • People's Hospital of Ningling County
      • Shangqiu, Porcelana
        • The First People's Hospital of Shangqiu
      • Shaoyang, Porcelana
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang, Porcelana
        • The People's Hospital of Gaocheng
      • Wuhan, Porcelana
        • Wuhan Puren Hospital
      • Xiangyang, Porcelana
        • Xiangyang NO.1 People's Hospital
      • Yibin, Porcelana
        • The second people's hospital of Yibin
      • Zhumadian, Porcelana
        • Zhumadian Central Hospital
      • Zhuzhou, Porcelana
        • Zhuzhou Central Hospital
      • Zigong, Porcelana
        • Zigong Third People's Hospital
      • Ziyang, Porcelana
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin, Heilongjiang, Porcelana, 150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou, Henan, Porcelana, 466300
        • Shenqiu County People's Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

70 años y mayores (Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

Comparador activo: Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Periodo de tiempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Periodo de tiempo: At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Periodo de tiempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
Periodo de tiempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
Periodo de tiempo: up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
Periodo de tiempo: At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Periodo de tiempo: up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
Periodo de tiempo: up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Periodo de tiempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de diciembre de 2025

Finalización primaria (Actual)

1 de noviembre de 2026

Finalización del estudio (Actual)

1 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

21 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

7 de diciembre de 2025

Publicado por primera vez (Actual)

19 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2025IITDA10

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir